The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
Abstract
Because of the pathological role of IL-6 in rheumatoid arthritis (RA), tocilizumab (TCZ), a humanized anti-IL-6 receptor monoclonal antibody, was expected to improve inflammation and joint destruction of RA. Indeed, randomized clinical trials demonstrated the clinical efficacy of TCZ as monotherapy or combined with methotrexate (MTX) for RA patients with inadequate responses to disease-modifying antirheumatic drugs, MTX or tumor necrosis factor (TNF) inhibitors. Although long-term tolerability for TCZ is superior to that for TNF inhibitors, information regarding the potency of drug free remission of TCZ is limited at present. In terms of its safety profile, the general risk of infection when using TCZ is comparable to that of TNF inhibitors. TCZ has some advantage in RA patients who can not use MTX and are non-responders to TNF inhibitors. In conclusion, TCZ is one of the most prospective next generation biologics for the treatment of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Tocilizumab showed protective efficacy against joint destruction and suppressed disease activity (Ogata et al., 2012”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Ogata et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139
Self-citationKishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
IL‐6: Regulator of Treg/Th17 balance
Kimura, A., & Kishimoto, T. (2010) · European Journal of Immunology · doi:10.1002/eji.201040391 · Cited by 1,595
Smolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Interleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Research works printed but not linked: 8
- Ogata A., 2011, Joint Bone Spine.
- Nishimoto N., 2003, J Rheumatol., 30, 1426
- Singh J.A., 2010, Cochrane Database Syst Rev., 70, CD008331
- Yazici Y., 2011, Ann Rheum Dis.
- Hoshi D., 2011, Mod Rheumatol.
- Okada M., 2011, Clin Dev Immunol., 404929
- Hirao M., 2011, Rheumatol Int.
- Singh J.A., 2011, Cochrane Database Syst Rev., CD008794
Cited by
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Self-citation
Metadata
- Authors
- Ogata, A., Hirano, T., Hishitani, Y., & Tanaka, T.
- Affiliations
- Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka University, Osaka, Japan.
- Venue
- Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
- Publisher
- SAGE Publications
- Published
- 2012-01
- Volume
- 5
- Pages
- CMAMD.S7371
- ISSN
- 1179-5441
- PMC
- PMC3306224
- Cited by
- 61
- References
- 86
- Language
- en
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
